Session I Case Studies of Infectious Agents Associated with Chronic DiseasesEvidence continues to mount implicating microorganisms as etiologic agents of chronic diseases that contribute to substantial mortality and morbidity. This session will examine definitive and emerging associations between infectious agents and chronic diseases with a range of pathogenic mechanisms and diversity in etiologic microbes. The review will explore advances in research, detection, and
|
|
|||||||||||||||||||||||||||||||
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 187
The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects - Workshop Summary
Appendix A
Workshop Agenda
LINKING INFECTIOUS AGENTS AND CHRONIC DISEASES:
Defining the Relationship, Enhancing the Research, and Mitigating the Effects
October 21–22, 2002
Room 100
The National Academies
500 Fifth Street, NW
Washington, DC 20001
AGENDA
MONDAY, OCTOBER 21, 2002
8:30 a.m.
Continental Breakfast
9:00
Welcome and Opening Remarks
Adel Mahmoud, Chair, Forum on Microbial Threats
Stanley Lemon, Vice Chair, Forum on Microbial Threats
Session I Case Studies of Infectious Agents Associated with Chronic Diseases
Evidence continues to mount implicating microorganisms as etiologic agents of chronic diseases that contribute to substantial mortality and morbidity. This session will examine definitive and emerging associations between infectious agents and chronic diseases with a range of pathogenic mechanisms and diversity in etiologic microbes. The review will explore advances in research, detection, and
OCR for page 188
The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects - Workshop Summary
screening that have contributed to these discoveries and some of the challenges that remain.
9:15
Human papillomavirus infection as the cause of cervical cancer
Eduardo Franco, McGill University
9:45
Infectious agents and cardiovascular disease
Michael Dunne, Pfizer, Inc.
10:15
Infectious agents and demyelinating diseases
Richard Johnson, Johns Hopkins University School of Medicine
10:45
The role of infectious agents in schizophrenia, bipolar disorder, and other serious neuropsychiatric diseases
Robert Yolken and E. Fuller Torrey, Johns Hopkins University School of Medicine and Stanley Foundation
11:15
BREAK
11:30
Common infections and uncommon disease: Elusive associations of enteroviruses and type I diabetes mellitus
Mark Pallansch, Centers for Disease Control and Prevention
12:00 p.m.
Chronic hepatitis B virus infections
William Mason, Fox Chase Cancer Center
12:30
Retrovirus-induced lung cancer in sheep:
Perspectives on the human disease
Hung Fan, University of California, Irvine
1:00
LUNCH
Session II Challenges in Framing the Research
Identification and confirmation of the infectious causation of chronic diseases are complicated by several factors, which include detection of microbes at the time of diagnosis of the chronic condition, the lack of adequate methods to identify novel or rare microorganisms, and the influence of environmental and genetic factors on the etiology of the chronic diseases. This session will examine these challenges and identify existing and potential methods and technologies for overcoming these obstacles.
OCR for page 189
The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects - Workshop Summary
2:00
Kaposi’s sarcoma, KSHV and causality: Koch’s postulates in the age of molecular biology
Patrick Moore, Mailman School of Public Health, Columbia University
2:30
Microbial agents in chronic diseases: Guilt by association versus pathologic etiology
Thomas Quinn, Johns Hopkins University School of Medicine
3:00
Novel diagnostic, therapeutic, and chemopreventive strategies
David Persing, Corixa Corporation
3:30
BREAK
Session III Discussion Panel: Shaping the Research and Development Agenda
3:45 Panel members, Forum members, and the audience will comment on and respond to considerations such as the role of industry in developing diagnostics; possibilities for the coordination between basic and clinical scientists, pathologists, and epidemiologists in developing standardized specific case definitions and specimens and the development of comparable methods of analysis; the lessons that can be learned about the microbes from the chronic sequelae they produce; and methods for funding the research.
David Morens, National Institute of Allergy and Infectious Diseases
Ian Lipkin, University of California, Irvine, and Mailman School of Public Health, Columbia University
Susan Swedo, National Institute of Mental Health
5:30
Adjournment of the first day
TUESDAY, OCTOBER 22, 2002
8:30 a.m.
Continental Breakfast
9:00
Opening Remarks
OCR for page 190
The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects - Workshop Summary
Session IV Implications for Developing Countries
As researchers, clinicians, and policymakers have recognized the growing disease burden from chronic diseases in developing countries, understanding of the infectious etiology of these diseases becomes increasingly important in these areas where many infectious diseases still remain endemic. This session will review the consequences of highly prevalent infectious diseases linked to chronic diseases and explore the global and local response needed to combat these outcomes in resource-limited environments.
9:15
Interaction of multiple infectious agents in endemic areas
Altaf Lal, Centers for Disease Control and Prevention
9:45
Progression of hepatitis C virus infection with and without schistosomiasis
Sanaa Kamal, Ain Shams University, Cairo, Egypt
10:15
Infectious agents and epilepsy
J.W.A.S. Sander, Institute of Neurology, University College, London
10:45
Potential long-term consequences of early childhood enteric and parasitic infections
Richard Guerrant, University of Virginia School of Medicine
11:15
HTLV-1: Clinical impact of chronic infection
Eduardo Gotuzzo, University of Peru, Lima, Peru
12:00 p.m.
LUNCH
Session V Barriers and Opportunities to Detect, Prevent, and Mitigate the Impact of Chronic Diseases Caused by Infectious Agents
The complexity of the relationship between infectious agents and chronic diseases requires a multi-disciplinary approach to reveal the implications of early detection and prevention of chronic diseases caused by infectious agents. This session will summarize the advances and gaps in collaborative research on detection and diagnostic technologies, their integration with epidemiological studies and surveillance that can forward the efforts in this important area, and the implications for clinical management practices and priorities.
OCR for page 191
The Infectious Etiology of Chronic Diseases: Defining the Relationship, Enhancing the Research, and Mitigating the Effects - Workshop Summary
1:00
Testing the reliability of the causal relationship: Considering genetic and environmental susceptibility
Mikhail Pletnikov, Johns Hopkins University School of Medicine
1:30
DNA sequence analysis of a stealth-adapted simian cytomegalovirus
W. John Martin, Center for Complex Infectious Diseases
2:00
Development of vaccines to prevent chronic disease
P. Helena Mäkelä, National Public Health Institute, Helsinki, Finland
2:30
Integrating epidemiology, laboratory research, and surveillance
Siobhán O’Connor, Centers for Disease Control and Prevention
3:00
BREAK
Session VI Discussion Panel: The Next Steps for the Healthcare Community
Panel members, Forum members, and the audience will comment on and respond to considerations such as the role of industry and academic research in developing treatments; the implications for the health care and prevention community in detecting and treating these diseases; and the benefits of managing acute infections vs. chronic diseases—the argument for vaccines and antimicrobials.
3:15
Kathryn Carbone, FDA, Center for Biologics Evaluation and Research
Thomas Shinnick, Centers for Disease Control and Prevention
5:00
Closing Remarks / Adjournment
Representative terms from entire chapter:
chronic diseases